U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) March 18, 2013

GREATBATCH, INC.
(Exact name of registrant as specified in its charter)

Delaware	**1-16137**	**16-1531026**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

2595 North Dallas Parkway, Suite 310, Frisco, Texas	**75034**
(Address of principal executive offices)	**(Zip Code)**

Registrant's telephone number, including area code (716) 759-5600

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240 14a-12).

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 7.01 Regulation FD Disclosure

On March 18, 2013, representatives of Greatbatch, Inc. (the "Company") delivered a presentation to analysts and investors at the Company's Investor Day held in New York, New York. As part of this presentation, management of the Company provided certain financial information including projections of future revenue, adjusted operating margin, adjusted operating cash flows and adjusted net income and EPS. This presentation is attached as Exhibit 99.1.

NON-GAAP FINANCIAL MEASURES

The attached presentation contains non-GAAP financial measures. Non-GAAP financial measures should be viewed in addition to, and not as an alternative for, the Company's reported results prepared in accordance with GAAP. In this presentation: "adjusted" amounts consist of GAAP amounts (or forecasted GAAP amounts) excluding (i) acquisition-related charges, (ii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iii) asset write-down and disposition charges, (iv) severance charges in connection with corporate realignments or a reduction in force (v) litigation charges and gains, (vi) the impact of non-cash charges to interest expense due to the accounting change governing convertible debt, (vii) unusual or infrequently occurring items, (viii) certain RD&E expenditures, such as design verification testing ("DVT") expenses incurred in connection with the development of our neuromodulation platform, (ix) gain/loss on the sale of investments, (x) the income tax (benefit) related to these adjustments and (xi) certain tax charges related to the consolidation of our Swiss Orthopaedic facility. We believe that reporting these amounts provides important supplemental information to our investors and creditors seeking to understand the financial and business trends relating to our financial condition and results of operations. Please see our 2012 Form 10-K filed with the SEC on February 27, 2013 for a reconciliation of the non-GAAP measures contained in this presentation.

CAUTIONARY STATEMENT

The statements made in the attached presentation that are not statements of current or historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. These forward-looking statements include statements relating to:

- future sales, expenses and profitability;
- future development and expected growth of our business, industries and markets;
- our ability to execute our business model and our business strategy;
- our ability to identify trends within our industries and markets and to offer products and services that meet the changing needs of those markets; and
- projected capital and other expenditures.

You can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or "variations" or the negative of these terms or other comparable

terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. We are under no duty to update any of these forward-looking statements or to conform these statements to actual results. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by the forward-looking statements contained in this presentation or that may affect our future results, some of these factors include the following: our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing pressure from customers; our ability to timely and successfully implement cost reduction and plant consolidation initiatives; our reliance on third party suppliers for raw materials, products and subcomponents; fluctuating operating results; our inability to maintain high quality standards for our products; challenges to our intellectual property rights; product liability claims; our inability to successfully consummate and integrate acquisitions and to realize synergies and to operate these acquired businesses in accordance with expectations; our unsuccessful expansion into new markets; our failure to develop new products including system and device products; our inability to obtain licenses to key technology; regulatory changes or consolidation in the healthcare industry; global economic factors including currency exchange rates and interest rates; the resolution of various legal actions brought against the Company; those risks set forth in our 2012 Form 10-K filed with the SEC on February 27, 2013; and other risks and uncertainties that arise from time to time.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.	
99.1	Greatbatch, Inc. Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 18, 2013

GREATBATCH, INC.

By: /s/ Michael Dinkins
Michael Dinkins
Senior Vice President and
Chief Financial Officer

Exhibit 99.1

Cautionary Statement

This presentation contains forward-looking statements, refers to non-GAAP financial measures and provides industry and market data. Please refer to the appendix to this presentation for more information and cautionary language regarding these statements, financial measures and data.

Disclaimers

This presentation includes products that have not been approved or cleared by the U.S. Food and Drug Administration and are not available for sale in the U.S.

All future product approval and launch dates are based on estimates of completion of regulatory submissions, review and/or approval or clearance, as well as other business considerations.

Greatbatch Presenters

Thomas Hook
President & CEO

Michael Dinkins
Senior VP & CFO

Scott Drees
President Algostim, LLC

Strategic Evolution

Experience the transformation from components & sub-assemblies to complete medical device system capabilities

Agenda

	Time	Presenter
Welcome	1:00 PM	Thomas Hook
Key Messages	1:05 PM	Thomas Hook
Sustainable Organic Growth	1:15 PM	Thomas Hook
Commercialize Medical Device Innovation	2:00 PM	Scott Drees
Break	2:40 PM	
Drive Profitable Growth	2:50 PM	Michael Dinkins
Closing Summary	3:10 PM	Thomas Hook
Q&A	3:20 PM	Leadership Team
Concludes	4:00 PM	

Greatbatch

Key Message Points

Sustainable Long-Term Growth



~ 5%
Organic Growth

Leverage IP
Innovation

~ 2x Top Line Growth
Adjusted EPS

Greatbatch

Greatbatch Today

$646M

2012 Revenue

88%

Revenues from Medical Device Market



Cardiac & Neuromodulation

Batteries | Capacitors | Catheters | Stimulation Leads | Feedthroughs | Device Enclosures & Cases | Device Headers | Device Assembly

Header

Feedthrough

Battery

Enclosure

Stimulation Leads

Orthopaedics

Implants | Instruments | Delivery Systems

Reamer Handle

Reamer

Delivery System

Handles

Vascular

Advanced Coatings | Catheters | Introducers

Steerable Sheath

Introducers

Portable Medical

Powered External Medical Devices

Battery Packs

Charging Stations

Integrated Power Supplies

Portable Medical to Greatbatch

Portable Medical Devices

Powered, external medical devices which enable movement and portability for the medical professional, patient and / or caregiver

Greatbatch's Focus

Greatbatch is committed to providing reliable, high quality power supplies, charging systems, and assembly to this market

Our Vision

Greatbatch will be the definitive leader in critical technologies by infusing integrity, innovation, and operational excellence into the medical device and commercial markets.

Our Strategy

Extend partnerships with key OEM customers beyond discrete components to include medical device systems.

Welcome

Key Messages

Sustainable Organic Growth

Commercialize Medical Device Innovation

Drive Profitable Growth

Closing Summary

Greatbatch

Sustainable Organic Growth

Targeted Markets

Strategic Investments

Supported Business Model

Sales Force Emphasis

Targeted Market Revenue



($ in millions)

	2012 Revenue	% of Total
Cardiac & Neuromodulation	$309	48%
Orthopaedics	$122	19%
Portable Medical	$82	13%
Vascular	$52	8%

88%

Revenues from Medical Device Market

Greatbatch Market Opportunities: Medical

Cardiac & Neuromodulation

GB Opportunity: $1.5B
GB Revenue: $309M
Avg. Market CAGR: 3%

- Pacemakers
- ICDs and CRT-D
- Implantable Monitors
- Spinal Cord Stimulation
- Peripheral Nerve Stimulation
- Cochlear
- Cardiac Surgery
- Ventricular Assist Devices

Orthopaedics

GB Opportunity: $3B
GB Revenue: $122M
Avg. Market CAGR: 5.5%

- Fracture Repair
- Joint Arthroscopy
- Spine
- Orthobiologics
- Joint Reconstruction
- Extremities
- Deformities
- Dental
- Maxillofacial

Portable Medical

GB Opportunity: $1B
GB Revenue: $82M
Avg. Market CAGR: 6%

- Defibrillators
- Ultrasound
- Staplers / Clips
- Auto CPR
- Oxygen Concentrators
- Ventilators
- Orthotics & Prosthetics
- Patient Monitors

Vascular

GB Opportunity: $1.3B
GB Revenue: $52M
Avg. Market CAGR: 3.5%

- Vascular Access
- Atrial Fibrillation
- Interventional Cardiology
- Peripheral Interventions
- Structural Heart
- Renal Denervation
- Dialysis
- Fluid Management
- Oncology

See appendix of this presentation for footnote on industry and market data

Sustainable Organic Growth

Greatbatch

Cardiac & Neuromodulation

Cardiac & Neuro Markets
Market Size / Estimated CAGR

Established GB Market Participation

• Pacemaker	$3.5B / (2%)
• ICD	$5.9B / (2%)
• Spinal Cord Stim	$1.4B / 7%
• Vagal Nerve Stim	$0.2B / 16%

Expanding GB Market Participation

• Implantable Monitors	$0.2B / 9%
• Deep Brain Stim	$0.4B / 17%
• Sacral Nerve Stim	$0.4B / 16%
• LVAD	$0.6B / 13%
• Cochlear	$0.8B / 12%

Adjacent GB Market Opportunities

• Cardiac Surgery	$1.4B / (1%)

See appendix of this presentation for footnote on industry and market data

GB Opportunity: $1.5B Avg. Market CAGR: 3%

Strategies

- Drive rechargeable battery offerings into broader neuromodulation markets
- Leverage existing technologies to drive growth in emerging & adjacent segments
- Increased customer focus to increase 'share of customer'

Orthopaedics

$3B Greatbatch Opportunity
Avg. Market CAGR: 5.5%

Greatbatch
5th Largest Supplier

Greatbatch Participation

Competitive 2012

Greatbatch 2012

Strategies

- Secure LTAs and improved pricing discipline
- Improved sales force productivity in core products & through product re-launches
- Portfolio mapping to drive new development initiatives
- Take advantage of consolidation opportunities among large number of segmented suppliers

See appendix of this presentation for footnote on industry and market data

Sustainable Organic Growth

Greatbatch

Portable Medical

Portable Medical Markets:
Market Size / Estimated CAGR

Established GB Market Participation

Auto CPR	$50M / 13%
Staplers / Clips	$1.8B / 4%
Defib (AEDs)	$1.6B / 8%
O_2 Concentrators	$0.8B / 7%

Expanding GB Market Participation

Patient Monitors	$2.3B / 5%
Orthotics-Prosthetics	$3.5B / 7%
Ventilators	$2.8B / 4%
Portable Ultrasound	$0.3B / 20%

Adjacent GB Market Opportunities

Powered Ortho	$0.5B / 6%
Anesthesia	$0.5B / 3%
Wound Therapy	$0.4B / 8%

See appendix of this presentation for footnote on industry and market data

Greatbatch Opportunity:
$1B Power Supply Market
Avg. Market CAGR: 6%



Strategies

- Target expanded opportunities within customer base
- Own more of the revenue for individual products
- Targeted M&A

Greatbatch

Vascular

$1.3B Greatbatch Opportunity
Avg. Market CAGR: 3.5%

Greatbatch Participation
Specialty Catheters
Vascular Introducers

Specialty Catheter Market Opportunity: $1.1B



Vascular Introducer *(venous)* Market Opportunity: $180M

Sustainable Organic Growth

Specialty Catheter Markets

Electrophysiology
Market Size $125M CAGR: 12%

Peripheral Vascular
Market Size $430M CAGR: 4%

Interventional Cardiology
Market Size $400M CAGR: 0%

Greatbatch 2012

Competitive 2012

Strategies

- Leverage technologies to drive growth in adjacent clinical segments with existing customer base
- Portfolio mapping to drive new development initiatives
- Continued execution of introducers re-launch campaign

See appendix of this presentation for footnote on industry and market data

Greatbatch

Aggregate Opportunity

- Multi Billion Dollar end markets served
- $6.8B Total Greatbatch Opportunity
- $565M GB Share of Opportunity *(8.7%)*
- Major growth opportunity through market share capture

Supported Business Model

Targeted Markets

Strategic Investments

Supported Business Model

Sales Force Emphasis

Sustainable Organic Growth

Greatbatch

Blue Chip Customer Base

Expanding Intellectual Property

Issued Patents: 1990 to 2012



Med Device Patents
Issued: 160
Pending: 57

593 (307 US)
Patents Pending

Long-Term Agreements

71%

- Greatbatch Medical revenue under LTAs
  - Current *(through 2013)*



Terms

65% - 70%	Through 2014
50%+	Through 2015
35% - 40%	Beyond

... in addition, product lifecycle / replacements drive core growth and protection

Portable Medical: Long Product Life Cycles

Design wins early with key OEMs & in emerging segments fuel long term growth



Sustainable Organic Growth

Greatbatch

Portable Medical: Long Product Life Cycles

Focus on Portfolio Management and IP wins generational development

Growth of AED and Defibrillator Battery Markets

Sustainable Organic Growth

Greatbatch

Strategic Investments

Targeted Markets

Strategic Investments

Supported Business Model

Sales Force Emphasis

Sustainable Organic Growth

Greatbatch

Operations Efficiency & Investment



Investment

- Low cost manufacturing operation established
- Medical device assembly capabilities
- Dedicated R&D centers

*Investments & Consolidations represent only a partial listing during the period

Consolidation

- Reduced operational burden
- Eliminated underperforming product lines
- Established unified resource locations
- Shed low margin programs
- Expanded capacity
- Enhanced Orthopaedics production environment
- Pursuing on-going cost reduction initiatives

Sustainable Organic Growth

Greatbatch

Orthopaedic Update

Completed milestones

- Transferred instruments and reamers from Switzerland
  - Net $4M Gross Profit improvement
- Divested $15M in non-profitable sales
- Successfully completed customer supplier certification audits at new manufacturing locations
- First production and shipment of transferred reamers Feb. 2013
  - Tijuana & Fort Wayne

Pending

- Additional transfers in process (consistent with guidance)

Quality: A Competitive Advantage

Integrate > Harmonize > Optimize

- Investment in leadership
- Harmonized quality systems
- Common enterprise quality metrics
- Product quality & capable system focus
- Talent & infrastructure development

Medical Device Infrastructure

- Over 100 years medical device quality leadership experience
- Nine ISO 13485 certified facilities
- Eight FDA registered facilities
- Successful FDA inspections
- On-going reduction in cost of quality

Medical Device Investment

Medical Device Manufacturing: Plymouth, MN

- Total Expansion: 27,000 sq ft
- Controlled Environment [Class 7]: 4,000 sq ft of space
- Adjacent Molding & Electrical Development Space
- FDA Registered Facility / Regulatory: ISO13485:2003, CMDCAS, AIMD & MDD

Acquisition Strategy

Focus on innovative technologies in our medical markets

Alignment with Strategy	• Aligned with therapy areas • Technology to leverage and fill gaps • Increasing market share via 'tuck-ins'
Address Technology Needs	• Differentiated product or procedures • Proprietary positioning of products • Feasibility of concept
Meet Financial Criteria	• Incremental revenue of $10 - $50M • Profitable ROI (>20%) • Accretive to sales growth, margins, and ROIC
Minority Investments	• Targeted investments of $5 - $10M • Equity positions ranging from 10 - 20% ownership • Align with long-term M&A guidelines

Sales Force Emphasis

Targeted Markets

Strategic Investments

Supported Business Model

Sales Force Emphasis

Sustainable Organic Growth

Greatbatch

Sales Leadership

Andrew Holman

VP Sales & Marketing, Greatbatch Medical

- 20 years experience working in medical device technologies
- Broad commercial medical technologies experience in urology/women's health, neurosciences, pain management and orthopaedics
- Prior experience includes: Boston Scientific, Johnson & Johnson, Smith & Nephew and DJO Global
- 4 Years B2B experience with Xerox Corporation

Greg Webster

VP Sales & Marketing, Electrochem

- 14 years experience working in Sales & Marketing providing power solutions
- Successful growth record with customers in medical, military and commercial markets
- Led sales teams to enable national and international expansion with Fortune 500 companies
- Implemented Strategic Account Program responsible for growing key accounts from $1-3M to $10-$30M+

Sales Force Optimization

Organized for Excellence

- Investment in leadership
- Customer relationship enhancement
- Distinct technical sales & account executives
- Upstream & downstream marketing additions
- Unified sales operations
- Enhanced rep recruiting

Equipped with Tools & Talent

- Focus on winning generational development programs
- Enhanced customer relationships & touch points
- Drive for additional LTAs
- New pay for performance structure; reps win when Greatbatch wins

Impactful Results

Welcome

Key Messages

Sustainable
Organic Growth

Commercialize Medical Device Innovation

Drive Profitable Growth

Closing Summary

Greatbatch

Scott Drees

President Algostim, LLC

- 32 years of experience working with implantable medical devices
- 16 years of neuromodulation market experience
- Founding Division President, Advanced Neuromodulation Systems Inc. (ANSI)
- Prior experience includes: St. Jude Medical, Boston Scientific, and Johnson & Johnson
- Board member: John Oakley Pain Research Foundation and Neuros Medical Inc.

Commercialize Medical Device Innovation

Leverage Capabilities

Strong Value Proposition

Technology Innovation

Addressing Unmet Needs

Future Opportunities

Capabilities Required For Active Implantable Systems

Leads & Accessories

- Mechanical Design
- Test Development
- Adhesive Processing
- Thermoplastic Molding
- Silicone Molding
- Extrusion
- Coil Winding
- Swiss Machining
- Tool and Die
- Laser Welding
- Resistance Welding
- Wire Coating & Cabling
- Center Less Grinding
- Thin Film Electrodes

Implantable Pulse Generators

- Industrial Design
- Finite Element Analysis
- Injection Molding
- Header Design and Development
- Titanium Enclosure Forming
- Hermetic Assembly Design
- Ceramic Brazing
- Charging Coil Development
- Laser Seam and Spot Welding
- Swiss Mach Part Design and Fabrication
- Stimulation and Pulse Generator Circuits
- Low Power Circuits Analog/Digital Design
- Embedded Systems Design
- Microprocessor Design/Controls
- ASIC Design, Development, Layout
- ASIC Architecture Design
- ASIC Fabrication
- Telemetry
- Transcutaneous Power and Recharging
- Antenna Design
- PCB Layout and Prototyping
- PCB Fabrication
- Electrical Test Station Development
- Lab View and Test Stand
- Mechanical Stress Testing
- Shock and Vibration Testing
- Automated Testing

Programmers & Software

- Microprocessor
- Firmware Design
- Power Management
- Battery Charging Software
- Wireless Communications
- Embedded Software Design
- Multiple Software Platform Development
- Graphical Interface Design
- 2D Modeling
- Software Coding Analysis
- Human Factors Engineering
- Device Driver Development
- Network Protocols

System Specs → System Design → ISO / Quality → Risk Mgmt → Labs → Tech Writing → Package Design

Neurostimulation Markets

FDA APPROVED

Deep Brain Stim:
Parkinson's Disease, Dystonia, Essential Tremor, Epilepsy, Obsessive Compulsive Disorder

Vagus Nerve Stim:
Depression, Epilepsy

Spinal Cord Stim:
Pain

Sacral Nerve Stim:
Urinary Incontinence, Fecal Incontinence

Percutaneous Tibial Nerve Stim:
Urinary Incontinence



EMERGING

Deep Brain Stim: Obesity, Stroke Recovery, Depression

Cortical Stim: Epilepsy

Peripheral Nerve Stim: Migraines, Extremity Pain

Carotid Artery, Sinus Stim: Hypertension

Hypoglossal & Phrenic Nerve Stim: Sleep Apnea

Spinal Cord Stim: Angina

Gastric Stim: Obesity

Sacral & Pudendal Nerve Stim:
Interstitial Cystitis, Sexual Function, Pelvic Pain

FUTURE

Deep Brain Stim:
Alzheimer's, Anxiety, Bulimia, Tinnitus, Traumatic Brain Injury, Tourette's, Sleep Disorders, Autism, Bipolar

Vagus Nerve Stim:
Alzheimer's, Anxiety, Obesity, Bulimia, Tinnitus, Obsessive Compulsive Disorder, Heart Failure

Spinal Cord Stim: Asthma

Gastric Stim: Bulimia, Interstitial Cystitis

Neurostimulation Market Sizes

Market Revenues *(W.W.)*

Average Market CAGR:
11% *(7% - 17%)*

2012: $2.6 B



2015: $3.6B



Source: Neuromodulation company earnings releases and internal estimates. Excludes cochlear, drug pumps; external stimulation

SCS: Spinal Cord SNS: Sacral Nerve
DBS: Deep Brain VNS: Vagus Nerve

SCS Market Acceleration

Market Drivers

- Advancing technologies
- Improving implantation techniques
- Greater awareness and referrals
- More implanting physicians
- Strong reimbursement
- Insurance approval
- Patients comfort with electronic devices

SCS 12 Year Market Growth & Share

Source: Neuromodulation company earnings releases and internal estimates

Greatbatch

Market Research

Physicians	Patients	Payers
• Ease of implant • Clinical performance • Lead options • Reliability and longevity • Simplified programming • Service	• Pain reduction • Discrete device • Easy to use • Comfortable & convenient • Covered by insurance • Company they can trust	• Cost effective products versus alternative therapies • Efficacy • Significant reduction in medication • Minimal complications

Physician Partners

Richard North, MD | *Chief Scientific Advisor*

- Director, Neuromodulation, Sandra and Malcolm Berman Brain & Spine Institute of LifeBridge Health, Baltimore, MD *(2007-present)*
- Professor of Neurosurgery, Anesthesiology & Critical Care Medicine, John Hopkins University School of Medicine *(1983-2007)*
- Founder and President, Stimsoft, Inc. *(sold to Medtronic in 2003)*
- Founder and President, The Neuromodulation Foundation, Inc
- Certified by the American Boards of Neurological Surgery and Pain Medicine
- Clinical experience with over 3,000 cases involving spinal cord stimulation during the last 28 yrs.
- 14 issued patents, 156 peer-reviewed publications, and over 500 lectures and presentations both nationally and internationally
- North American Neuromodulation Society's Lifetime Achievement Award

Giancarlo Barolat, MD | *Chief Medical Advisor*

- Director, Barolat Neuroscience Center at Presbyterian St. Luke's Hospital, Denver, CO *(2005-present)* and Director of Barolat Neuromodulation Institute Europa *(2011-present)*
- Professor of Neurosurgery at Thomas Jefferson University, Philadelphia *(1985-2005)*
- Founding Member and Board Member- American Neuromodulation Society
- Certified by both the American and by the Italian Board of Neurosurgery
- Most clinical experience in the world with over 7,000 neuromodulation procedures in 35 yrs.
- 8 issued patents, 84 published peer reviewed articles and book chapters, along with over 285 lectures and presentations both nationally and internationally
- AANS Lifetime Achievement Award

SCS Systems Today: Unmet Needs

IPG	Leads	Patient Programmers & Rechargers	Clinician Programmers
• Standardized configuration *(2x8)* • Poor tri-pole capabilities • Current steering • Complete discharge recovery • Limited parametric range • Biphasic square waveform • Inductive coupling • Unidirectional recharge • Restricted implant depth	**Percutaneous Leads** • Lead migration (13%)* • Lead breakage (9%)* • Limited coverage 1 - 2 spine levels • Inability to capture target • Need for splitters to achieve tri-pole stim **Paddle Leads** • Excessive volume • Blind positioning • Lack of steering control	• Designed for in-home use • Large and non-discrete • Button sequences are confusing • Small screens for feedback • No color or touch screens • Multiple devices for programmer/recharger • Lack recharge feedback • Inductive coupling required	• Time consuming • Non-intuitive • Dependent on sales team • Lack patient feedback mechanism • Awkward size devices • Lack visual clarity • Stylus required in handhelds • Inductive coupling required

*SOURCE: Cameron et al., 2003 & updated with 2009 AAPM poster

Product Strategy

- Target unmet clinical needs
- Focus on product differentiation for all user groups
- Procedurally the same - but better
- Legacy free, proprietary system
- Design focused on safety
- Allows efficient regulatory approval
- Gen 1: Technology innovation drives market share
- Gen 2: Breakthrough technology enables market leadership

"A product designed by doctors for doctors"

Richard B. North, MD

Algostim System

Commercialize Medical Device Innovation

Greatbatch

Algostim System Innovations

IPG

- 24 Channels
- Two Configurations
- Tri-Pole Capability
- Smallest Volume
- Thinnest Implant
- Largest Battery Capacity
- Broadest Parametric Ranges
- Bi-Directional Recharge
- MICS Wireless Telemetry
- Embedded Program Memory

Leads

Perc Leads

- 12 & 8 Contact Arrays
- Dual Coil Construction
- Body Compliant
- Lead ID System

Paddle Leads

- Thinnest >50%
- Smallest Volume >50%
- Body Compliant
- Multi-Midline Positioning
- Stylet Steering

Programmers/Software



- Color Touch Screen
- 3D Pain Mapping
- 3D Stim Mapping
- 3D Overlap Scoring
- CASP Algorithm
- CASP Feedback Device
- Camera / Barcode Reader
- Monitor Mirroring
- Combined Programmer / Charger
- Key Fob Programmer

Implantable Pulse Generator

Features

- 24 channels
- Two header configurations *(2x12 & 3x8)*
- Rechargeable battery
- Largest battery capacity
- Broadest parametric ranges
- Smallest & thinnest device
- Independent current sources
- Deep discharge recovery
- Constant current output
- MICS wireless telemetry
- Safety thermistor
- Bi-directional recharge
- Embedded memory

Percutaneous Lead Anatomy

12 & 8 contacts



3 electrode spacings
4 lead lengths

Lead Design Progression

Past | Present | Future



COIL DESIGN
COIL STRUCTURE
4-Electrode Leads

UNCONSTRAINED
STRAIGHT WIRE
8-Electrode Leads

INDEPENDENT
STRAIGHT WIRE
8 & 16-Electrode Leads

algostim
COIL IN COIL DESIGN
COIL STRUCTURE
8 & 12-Electrode Leads

Broader Coverage



Paddle Lead Standards



Current product limitations

- Excessive volume
- Blind positioning
- Lack of steering control
- Have no / limited body compliance


Surgical / Paddle Leads Anatomy
2x6
1mm
3-4-3-2
1mm
Stylet Lumen
4
8
Connector Coil
/ Cable
Connectors
to IPG
Electrodes
Silicone Paddle
Suture Locators
Coil Lead Body
Paddle Tail
Volume Reduction
Greatbatch
56

Thin Profile Paddle Leads

Programmer Family

Patient Programmers

Pocket Programmer

- Discrete key fob design
- Daily control functions
- Rechargeable device
- MICS wireless telemetry
- Quick stim-off

Programmer Charger

- Programming and recharging device
- Full control programming options
- Color touch screen interface
- MICS wireless telemetry
- Recharge location visual feedback
- Rechargeable device
- Quick stim-off

Clinician Programmers

Clinician Programmer

- Resistive color touch screen
- External monitor connection
- Embedded camera
- Rechargeable device
- SD card storage
- Bluetooth communication
- MICS wireless implant telemetry
- Quick stim-off

Patient Feedback Tool

'Computer Assisted Stimulation Programming'

- Automatic impedance check
- Stimulation threshold determination
- Patient identifies best stimulation coverage / optimal parasthesia patterns
- Bluetooth communication
- LED feedback
- Quick stim-off

Clinician Programmer Software

Software Features

- 3D Virtual Environment
- 3D Pain Mapping
- 3D Stimulation Mapping
- 3D Overlap Scores
- Computer Assisted Stimulation Programming *('CASP')*
- Presets for routine intra-operative trials
- Visual implant selector
- Patient programming history
- Secure log-ins
- Patient device emulator
- Auto report generation
- Bluetooth printer

Pain Mapping

Product Selection

CASP

Set Program

Pulse Generators

IPG

- Thermistor
- MICS Wireless Telemetry
- Deep Discharge Recovery Battery
- Bi-Directional Recharge
- High Voltage Protection Circuitry
- Independent Current Sources
- Internal Self-Checks
- Impedance Check
- Quick Stim-Off by External Devices

EPG

- Internal Self-Checks
- Easy Trial Cable Connect / Disconnect
- Quick Stim-Off
- Program Memory

Safety Features

Leads & Extensions

Perc & Paddle Leads, Extensions

- Minimize Size
- Coil In Coil Design
- Multiple Electrodes
- Active Capture Set Screw *(Extension)*

Accessories

Stylets

- Multiple Tips

Introducer Needle

- Flared & Radius Tip

Tunneling Tool

- Malleable Rod & Tip
- 2 Length Options
- Accommodates 3 Leads

Programmers

All Programmers

- Battery Status of IPG
- Paired to Single IPG / EPG
- MICS Wireless Telemetry
- Quick Stim-Off

Programmer Charger

- Rechargeable Device During IPG Recharge
- Recharge Location Feedback
- Recharge Temperature Sensing

Clinician Programmer

- Log-Ins for Different Users
- Monitor Mirroring
- Camera / Image Storage
- Charge Density Limits
- Model Based Implant Selection

Patient Feedback Tool

- 'CASP' *(Computer Assisted Stimulation Programming)*

Regulatory Plan

Proposed Indication

The Algostim Spinal Cord Stimulation *(SCS)* System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.

History

Company *(Product)*	Original PMA	Supplements
Medtronic (Itrel)	1984	233+
St. Jude (Genesis)	2001	65+
Boston Scientific (Precision)	2003	153+

Plan

- Pursue PMA approval *(literature based PMA)*
- Utilize pre-IDE / PMA process
- Obtain CE mark
- TÜV *(notified body)* utilizing modular review process

Greatbatch

Next Generation

IPG Embedded Capabilities

- High Frequency Stimulation
- 3-axis accelerometer
- Novel waveforms & wave shaping

Lead Designs

- Thin-film perc lead designs
- 24+ electrode paddle leads

Thin-Film Paddle: 24+ Electrodes | Planar | Cylindrical



System Level

- MRI conditional system

Intellectual Property

- Greatbatch IP portfolio > 1000
- Algostim invention disclosures 135
- Filed patent applications 86
- Patent applications in draft 18
- Patents licensed Dr. North & Barolat 11
- Patents issued to date 6
- Patent opinions 77

IP Product Distribution

	Leads	IPGs	Programmers & Software	Accessories	Total
Disclosures	26	44	51	14	**135**
Applications	19	23	36	8	**86**
Opinions	20	39	17	1	**77**

Leveraging Our Capability

Commercialize Medical Device Innovation

Greatbatch


IPG
Plymouth:
Header
Plymouth:
Stackers
Plymouth:
End Cap
Clarence:
Set Screws
Minneapolis:
Enclosure
Clarence:
Set Screw Block
Tijuana:
Multi-pin
Feedthrough
Assemblies
Minneapolis:
Enclosure
Alden:
Battery
2412
algostim
Final Assembly: Plymouth
67

Leads & Extensions

Manufacturing: Plymouth

Programmers

Software

Batteries for Programmers

Software: Denver | **Portable Medical: Raynham**

Algostim Timeline



Strong Value Proposition

Leverage Capabilities

Technology Innovation

Addressing Unmet Needs

Strong Value Proposition

Future Opportunities

Impact to Customer Groups

Physicians

- No change to implant procedures
- Improved body compliant lead design & steering control
- Broader stimulation coverage
- Multiple IPG options
- Long list of Safety Features
- Highly visual & intuitive programmers
- Intraoperative visibility and engagement of surgical staff
- Patient interactive programming

Patients

- Portable & Discrete External Products
- Simple and familiar user interfaces
- Comfortable system for screening, recharge and daily transport
- Fits existing reimbursement standards

Value Proposition

"A highly differentiated complete SCS system and platform with extensive offering of innovation, IP, advanced safety features, and future generation capabilities in the fast growing $1.4B SCS market"

- 1% market share represents $17M revenue to partner in 2015
- Highly under penetrated market *(<10%)*
- History of large market share shifts with technology innovation
- Strong SCS growth rate *(7%+ CAGR)*
- Extensive IP portfolio
- Gen 1: Technology innovation will drive market share
- Gen 2: Breakthrough technology can enable market leadership

Leverage Medical Device System Capabilities

algostim TECHNOLOGIES
Relieving Pain. Restoring Life.

- Deliver on complete system initiative
- Investment in capabilities
- Platform technology for additional opportunities

Future NewCo's

- Approved & emerging indications

CardiomoniX
Monitoring the Rhythm of Life

- Entry into cardiac systems
- Implantable Loop Recorder
- Address unmet needs
  - Remote monitoring
  - High quality data

Welcome

Key Messages

Sustainable
Organic Growth

Commercialize Medical
Device Innovation

Drive Profitable Growth

Closing Summary

Greatbatch

Drive Profitable Growth

Increasing Margins

~ 5% Organic Revenue Growth

Strong Balance Sheet & Cash Flow

Targeted M&A

Med Device Upside

Sustainable Long-Term Growth



~ 5%
Organic Growth

Leverage IP
Innovation

~ 2x Top Line Growth
Adjusted EPS

Drive Profitable Growth

Greatbatch

Aggregate Opportunity

- Multi Billion Dollar end markets served
- $6.8B Total Greatbatch Opportunity
- $565M GB Share of Opportunity *(8.7%)*
- Major growth opportunity through market share capture

Core Business Growth Drivers

Drive Profitable Growth

Greatbatch

Strength of Core Business

2012 Performance of Core Business

Exclusive of Medical Device Initiative Spend

Adjusted Op Margin* | **Adjusted EPS***

*See appendix of this presentation for a reconciliation to GAAP amounts.

Drive Profitable Growth

Greatbatch

2013 Guidance

Increasing Margins

~ 5% Organic Revenue Growth

Strong Balance Sheet & Cash Flow

Targeted M&A

Med Device Upside

Drive Profitable Growth

Greatbatch

2013 Assumptions

Assumptions

- Completion of Swiss Consolidation in Q1 2013
- No acquisitions are included although we are actively engaged in looking for accretive deals that will improve our operating revenue growth performance
- Impact of R&D commercialization not included in guidance (Algostim, MRI, Sensor)
- Medical Device Tax estimated impact on Gross Profit $1.5M to $2.5M
- Estimated 33% to 35% tax rate (includes only the 2013 benefit of the recently reenacted R&D tax credit)

Revenue Growth

($ in millions)

	2012 Revenue	2013E Annual Growth Revenue	2013E Revenue
Cardiac & Neuromodulation	$309	0 – 2%	$309 – 315
Orthopaedic (1)	$122	(5) – 0%	$116 – 122
Portable Medical	$82	15 – 20%	$94 – 98
Vascular Access	$52	7 – 13%	$55 – 59
Energy & Other	$81	6%	$86 – 86
Total Sales	$646	2 – 5%	$660 – 680

(1) Organic growth for orthopaedic product line is 8% - 14% due to disposition of $15 million of non-core product lines at the end of 2012. Total company organic growth is expected to be 5% - 8%.

2013 Guidance

($ in millions except for EPS)

	2012	2013E	Change	2013E w/o Device Spend
Sales	$646	$660 – 680	2 – 5%	$660 – 680
Adjusted Operating Margin (1)	11.4%	12 – 12.5%	60 – 110 bps	16 – 17%
Adjusted Diluted EPS (1)	$1.77	$1.90 – 2.00	7 – 13%	$2.62 – 2.67
Adj. Operating Cash Flows (2)	$80	~$90	12 – 13%	
Capex	$41	$20 – 30	(51) – (27)%	
ROIC	7.4%	~8%	~60 bps	

(1) See appendix of this presentation for a reconciliation to GAAP amounts.

(2) Excludes the impact of other operating and DVT expenses of $10M (2013) and $15M (2012) and the deferred tax payment on the redemption of our convertible debt in 2013 of $30M.

Strength of Core Business

2013 Estimate of Core Business

Algostim & targeted M&A represent additional upside

Adjusted Op Margin* | **Adjusted EPS***

*See appendix of this presentation for a reconciliation to GAAP amounts.

EPS Improvement

Drive Profitable Growth

Greatbatch

Strong Operating Cash Flow

*Excludes the impact of other operating and DVT expenses of $10M and the deferred tax payment on the redemption of our convertible debt in 2013 of $30M.

Consistent Cash Flow Drives Lower Leverage

5 year annual average of $79M

Debt repayment of $129M from 2009 to 2012

*Excludes the impact of other operating and DVT expenses of $10M and the deferred tax payment on the redemption of our convertible debt in 2013 of $30M.

Drive Profitable Growth

Greatbatch

Capacity for Growth Opportunities

Credit facility matures June 2016

Utilized Line of Credit to finance converts redeemed Feb 2013

$600 M
Line of Credit

QiG Business Model

Increasing Margins

Strong Balance Sheet & Cash Flow

~ 5% Organic Revenue Growth

Targeted M&A

Med Device Upside

Drive Profitable Growth

Greatbatch

Avenues of Development

Investment Mechanism	Partner	Funded	Examples
Strategic Investments	**Entrepreneur / Early Stage Company**	**Balance Sheet**	• **Intelect** • **Sapiens** • **DeCheng**
OEM Initiated Medical Device Development	**Partner Customers**	**NRE** Non-Recurring Engineering	*8 In-process* *14 Complete* *(since 2010)*
Market Driven Medical Device & System Development	Clinicians *(KOLs)* & *Distribution Partners*	Historically P&L Transitioning to 3rd Party	• Coatings • MRI • Algostim • CardiomoniX

Drive Profitable Growth

Greatbatch

Development Model

ROI
License or
Sale

Manufacturing
Revenue

Greatbatch & 3rd Party Funded

Enhanced Margin

Phase **Design & Development**

Commercialization
3rd Party

Manufacturing
& Continuation

CONCEPT | DETAILED DESIGN | VERIFICATION & VALIDATION | REGULATORY

SALES AND DISTRIBUTION BY OEM PARTNERS

DEVICE MANUFACTURING

FINAL STERILE PRODUCT

Markets:

Cardiac

Neuromodulation

Orthopaedics

Vascular

Portable Medical

Medical Device Spend Reducing

Total QiG Spend



Drive Profitable Growth

Greatbatch


Welcome
Key Messages
Sustainable Organic Growth
Commercialize Medical Device Innovation
Drive Profitable Growth
Closing Summary
Greatbatch
94

Key Message Points

Q&A Panel

Greatbatch

Thomas J. Hook
President & CEO

Michael Dinkins
Senior Vice President & CFO

Scott Drees
President Algostim

Susan M. Bratton
President Electrochem

Daniel R. Kaiser
Vice President & CTO

Contact Information

Michael Dinkins

Chief Financial Officer

Greatbatch, Inc.

2595 Dallas Parkway
Suite 310
Frisco, TX 75034
Tel: 214-618-5242
MDinkins@greatbatch.com
www.greatbatch.com

Greatbatch

Appendix

Forward Looking Statement

The statements made in this presentation and in the oral remarks accompanying these slides that are not statements of current or historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. These forward-looking statements include statements relating to:

- future sales, expenses and profitability;
- future development and expected growth of our business, industries and markets;
- our ability to execute our business model and our business strategy;
- our ability to identify trends within our industries and markets and to offer products and services that meet the changing needs of those markets; and
- projected capital and other expenditures.

You can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or "variations" or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. We are under no duty to update any of these forward-looking statements or to conform these statements to actual results. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by the forward-looking statements contained in this presentation or that may affect our future results, some of these factors include the following: our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing pressure from customers; our ability to timely and successfully implement cost reduction and plant consolidation initiatives; our reliance on third party suppliers for raw materials, products and subcomponents; fluctuating operating results; our inability to maintain high quality standards for our products; challenges to our intellectual property rights; product liability claims; our inability to successfully consummate and integrate acquisitions and to realize synergies and to operate these acquired businesses in accordance with expectations; our unsuccessful expansion into new markets; our failure to develop new products including system and device products; our inability to obtain licenses to key technology; regulatory changes or consolidation in the healthcare industry; global economic factors including currency exchange rates and interest rates; the resolution of various legal actions brought against the Company; those risks set forth in our 2012 Form 10-K filed with the SEC on February 27, 2013; and other risks and uncertainties that arise from time to time.



Non-GAAP Financial Measures

This presentation contains non-GAAP financial measures. Non-GAAP financial measures should be viewed in addition to, and not as an alternative for, the Company's reported results prepared in accordance with GAAP. In this presentation: "adjusted" amounts consist of GAAP amounts (or forecasted GAAP amounts) excluding (i) acquisition-related charges, (ii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iii) asset write-down and disposition charges, (iv) severance charges in connection with corporate realignments or a reduction in force (v) litigation charges and gains, (vi) the impact of non-cash charges to interest expense due to the accounting change governing convertible debt, (vii) unusual or infrequently occurring items, (viii) certain RD&E expenditures, such as design verification testing ("DVT") expenses incurred in connection with the development of our neuromodulation platform, (ix) gain/loss on the sale of investments, (x) the income tax (benefit) related to these adjustments and (xi) certain tax charges related to the consolidation of our Swiss Orthopaedic facility. We believe that reporting these amounts provides important supplemental information to our investors and creditors seeking to understand the financial and business trends relating to our financial condition and results of operations. Please see our 2012 Form 10-K filed with the SEC on February 27, 2013 for a reconciliation of the non-GAAP measures contained in this presentation.



Industry and Market Data

The industry and market data used in this presentation was obtained from our own research, internal surveys and studies conducted by third parties, independent industry associations or general publications and other publicly available information. Third party providers of this data generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. Forecasts are subject to change and are particularly likely to be inaccurate, especially over long periods of time.

Trademarks / Tradename

These presentation slides include trademarks, servicemarks and tradenames owned by other companies, including companies that are our customers, suppliers and competitors. All trademarks, servicemarks and tradenames included in these slides are the property of their respective owners.

GAAP Reconciliation

A reconciliation of GAAP operating income to adjusted amounts is as follows (dollars in millions):

	2013 Estimate	2012	2011	2010
Total sales	$ 660.0 - 680.0	$ 646.2	$ 568.8	$ 533.4
Operating income as reported	$ 65.2 - 73.5	$ 25.8	$ 61.7	$ 69.0
Adjustments:				
Inventory step-up amortization (COS)	-	0.5	0.2	-
Executive death benefits (SG&A)	-	-	-	0.9
Medical device DVT expenses (RD&E)	4.8 - 5.8	5.2	- 5.1	-
Electrochem litigation gain	-	-	-	(9.5)
Consolidation and optimization costs	6.2 - 7.2	39.0	- 0.4	1.6
Integration expenses	-	1.5	- -	-
Asset dispositions, severance and other	0.5 - 1.0	1.9	- 0.2	2.9
Adjusted operating income	$ 79.2 - 85.0	$ 73.9	$ 67.6	$ 64.9
Adjusted operating margin	12.0% - 12.5%	11.4%	11.9%	12.2%
Medical device related adjusted expenses (excluding DVT)	$ 25.0 - 27.0	$ 28.4	$ 22.1	$ 21.9
Adjusted operating income excluding medical device initiatives	$ 106.2 - 110.0	$ 102.3	$ 89.7	$ 86.8
Adjusted operating margin excluding medical device initiatives	16.1% - 16.2%	15.8%	15.8%	16.3%

Greatbatch

GAAP Reconciliation

A reconciliation of GAAP net income (loss) and diluted EPS to adjusted amounts is as follows (in millions, except per share amounts):

	2013 Estimate		2012		2011		2010	
	Net Income (Loss)	Impact per Diluted Share	Net Income (Loss)	Impact per Diluted Share	Net Income (Loss)	Impact per Diluted Share	Net Income (Loss)	Impact per Diluted Share
Net income (loss) as reported	$ 35.1 - 39.3	$ 1.44 - 1.62	$ (4.8)	$ (0.20)	$ 33.1	$ 1.40	$ 33.1	$ 1.40
Adjustments (a):								
Inventory step-up amortization (COS)	-	-	0.3	0.01	0.1	-	-	-
Executive death benefits (SG&A)	-	-	-	-	-	-	0.6	0.02
Medical device DVT expenses (RD&E)	3.1 - 3.8	0.13 - 0.16	3.4	0.14	3.3	0.14	-	-
Electrochem litigation gain	-	-	-	-	-	-	(6.2)	(0.26)
Consolidation and optimization costs	4.0 - 4.7	0.16 - 0.19	28.9	1.21	0.3	0.01	1.0	0.04
Integration expenses	-	-	1.0	0.04	-	-	-	-
Asset dispositions, severance and other	0.3 - 0.7	0.01 - 0.03	1.2	0.05	0.2	-	2.0	0.08
(Gain) loss on cost and equity method investments, net (b)	-	-	0.1	-	(2.8)	(0.12)	0.1	-
CSN conversion option discount amortization (c)	3.4	0.14	6.2	0.26	5.5	0.23	5.1	0.22
Swiss tax impact/R&D Tax Credits (d)	(1.5)	(0.06)	6.2	0.26	-	-	-	-
Adjusted net income and diluted EPS (e)	$ 46.2 - 48.6	$ 1.90 - 2.00	$ 42.5	$ 1.77	$ 39.7	$ 1.68	$ 35.7	$ 1.51
Medical device related adjusted expenses (excluding DVT)	16.2 -17.5	0.67 - 0.72	18.5	0.77	14.4	0.61	14.2	0.60
Adjusted net income and diluted EPS excluding medical device initiatives (e)	$ 63.7 - 64.8	$ 2.62 - 2.67	$ 61.0	$ 2.55	$ 54.1	$ 2.29	$ 49.9	$ 2.10
Adjusted diluted weighted average shares	24.3		23.9		23.6		23.8	

(a) Net of tax amounts computed using U.S. and foreign statutory tax rates of 35% and 22.5%, respectively, for items incurred in those geographic locations.
(b) Pre-tax amounts are a loss of $106 thousand for 2012, a gain of $4.2 million for 2011 and a loss of $150 thousand for 2010.
(c) Pre-tax amounts are $5.2 million for 2013, $9.6 million for 2012, $8.5 million for 2011 and $7.9 million for 2010.
(d) 2013 relates to the reinstatement of the R&D tax credits for 2012 and 2012 relates to the loss of our Swiss tax holiday due to our decision to transfer manufacturing out of Switzerland, as well as the establishment of a valuation allowance on our Swiss deferred tax assets as it is more likely than not that they will not be fully realized.
(e) The per share data in this table has been rounded to the nearest $0.01 and therefore may not sum to the total.